Use access key #2 to skip to page content.

Recs

5

How Can You Not Love Free Stocks?

February 27, 2017 – Comments (0) | RELATED TICKERS: JNJ

always keep an eye out for free or close to it Contingent Value Rights in pharma industry mergers. I have a couple of them in my portfolio right now. While the Actelion - JNJ deal isn't creating a CVR it is creating a similar special situation in a free R&D spinoff. Really the only risk here is the collapse of the merger, other than that the shares of the spinoff are essentially free...though they may not trade directly in the U.S.  [more]

Recs

3

Get Paid 10% to Wait for a Potential Catalyst at New Senior

February 16, 2017 – Comments (0) | RELATED TICKERS: SNR

As a fairly long-time shareholder of New Senior Investment Group (SNR), I have been fairly disappointed by the performance of the company's stock.  Despite the fact that by most metrics New Senior is significantly shearer than its industry peers and its whopping 10.2% yield the company doesn't seem to get any respect from investors.  I gets it to a certain degree, SNR is an externally managed REIT.  Externally managed REITs generally speaking are despised by Wall Street.  Furthermore, the company's manager, Fortress Investment Group (FIG), has seen very mixed results over the years.   [more]

Recs

2

Another positive for the GLDD Special Situation, but Is It Enough?

January 16, 2017 – Comments (1) | RELATED TICKERS: GLDD

I wrote a short blog post last month about all of the positives that a company called Great Lakes Dredge & Dock (GLDD) has going for it right now.   Dredging the Bottom for Stocks

http://caps.fool.com/Blogs/dredging-the-bottom-for-stocks/1078670   [more]

Recs

5

A Potential Special Situation Twist in Johnson & Johnson's Acquisition of Actelion

January 12, 2017 – Comments (0) | RELATED TICKERS: JNJ

Here's an interesting development in the potential acquisition of Actelion by Johnson & Johnson.  Often in the pharma industry in order to convince shareholders of the company being acquired to make a deal the acquirer will make contingent value rights part of the deal in order to enable the people who are being bought out to participate in the upside of drugs that are in the pipeline.  The tact that J&J is taking with Actelion sound like it will employ a different type of special situation, a partial spinoff of the firm's R&D department that would enable the Actelion shareholders who are being bought out to partially benefit from any future drug development.  Interesting.  The spinoff is one that I'll be keeping an eye on.  From all that I've rread on the subject thus far, analysts seem to like the Actelion acquisition from J&J's perspective as well.  [more]

Recs

3

Wow that didn't take long, Brookdale Soars

January 10, 2017 – Comments (0) | RELATED TICKERS: BKD

Wow that didn't take long.  I own a number of activist investor Land & Buildings' targets in real life and seriously considered buying into Brookdale Senior Living when I wrote about it here in late December.  I'm not sure why I didn't, other than possibly being distracted by the holidays.  Oh well, in mid-day trading today shares of Brookdale (BKD) spiked 15% on a report that the company is in talks to sell itself.  If the sale materializes, score another victory for Jonathan Litt.  [more]

Featured Broker Partners